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Introduction
Cancer is a major burden of disease and public health 
concern in world (Keyghobadi et al., 2014; Razi et al., 
2014). Among cancers, bladder cancer is the seventh most 
common cancer in men, while seventeenth most common 
cancer in women worldwide. It is considered the most 
common urinary tract and genital cancer (Akbari et al., 
2008; Burger et al., 2013; Ferlay et al., 2015). Over the past 
decade, bladder cancer was associated with a significant 
increase, so that in 2002, over 357,000 cases of bladder 
cancer were reported in the world (Murta-Nascimento et 
al., 2007). However, from almost 430,000 cases in 2012 
in the world, 165,000 people had died (Ferlay et al., 2013; 
Lyon, 2013; Malats and Real, 2015). The incidence of 
bladder cancer in men is three to four times higher than in 
women. Seven percent of all new cancer cases were men, 
but only women include 2% of new cases of the cancer 
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Abstract
 Background: Over the past decade, bladder cancer was associated with a significant increase. Given the 
importance of the impact of socioeconomic status on the distribution of cancer incidence and mortality, and the 
need to information on these parameters for prevention planning, the aim of this study was to evaluate data 
for bladder cancer and their relationship with human development index (HDI) and its components in Asia in 
2012. Materials and Methods: The study was conducted based on data from the world data of cancer and the 
World Bank (including the HDI and its components). The incidence and mortality rates were drawn for Asian 
countries. To analyze data, correlation tests between incidence and death rates, and HDI and its components were 
employed with a significance level of 0.05 using SPSS software. Results: A total incidence of 696,231 cases (68.7% 
in males and 31.3% in females, sex ratio of 2.19:1) and 524,465 deaths (67.0% in men and 32.9% in women, sex 
ratio was 2.03:1) were recorded in Asian countries in 2012. Correlation between HDI and standardized incidence 
rate was 0.241 overall (p=0.106), 0.236 in men (p=0.114) and -0.250 in women (p=0.094). Also between HDI and 
standardized mortality rate 0.025 (p=0.871) in men 0.118 (p=0.903) and in women 0.014 (p=0.927). Conclusions: 
Bladder cancer incidence is higher in developed countries, but the rate is declining, and in less developed and 
developing countries it is growing. There was no statistically significant correlation between the standardized 
incidence rate of bladder cancer and the HDI and its dimensions in Asia, except for the level of education.  
Keywords: Bladder cancer - incidence - mortality - HDI - Asia - development
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(Ahmadi et al., 2012). 
Distribution of cancer in the world is different. Two 
thirds of new cases of bladder cancer occur in developing 
countries (Ploeg et al., 2009; Yavari et al., 2009). The 
difference in the incidence of bladder cancer in the world 
may be not only for the causal factors, but also due to 
the cancer registry systems (Malats and Real, 2015). 
However, it is predicted cancer incidence in developing 
countries will increase in the future, and a greater burden 
is devoted to the disease (Ploeg et al., 2009). There are 
several causal factors for bladder cancer, but two main 
causes of the cancer are smoking and occupational 
exposure to chemicals in the environment (Kogevinas et 
al., 2003; Ploeg et al., 2009; Yavari et al., 2009). In terms 
of morphology, in developed countries, about 90% of 
all bladder cancer cases are transitional cell carcinoma, 
resulting from f the smoke and chemicals, 5% squamous 
cell carcinomas, and 2% adenocarcinomas. However, 
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in developing countries, 75% cases are squamous 
cell carcinomas, due to exposure to parasites, such as 
Schistosoma haematobium (Kirkali et al., 2005; Creel, 
2007), which is responsible for the incidence of most cases 
in Egypt, where the highest incidence of bladder cancer in 
the world (37.1 per 100,000) was observed (Ploeg et al., 
2009). It is estimated that the mortality rate for bladder 
cancer is 10 per 100,000 for men and 2.4 thousand per 
100,000 for women. Although the mortality rate for the 
cancer depends on the stage of cancer and development 
levels of a region. It is shown that the mortality rate for 
bladder cancer in developed countries has a decreasing 
trend in the last half century (Yavari et al., 2009). 
Incidence and prevalence of bladder cancer increases 
with age, so that the peak its incidence is the seventh and 
eighth decades of life (Malats and Real, 2015). Although 
screening is not recommended for bladder cancer, studies 
have shown that the use of Hematuria home screening 
can reduce deaths from bladder cancer (Messing et 
al., 1995; Botteman et al., 2003). Studies have shown 
that the incidence and survival of bladder cancer is so 
strongly influenced by socioeconomic status. In other 
words, bladder cancer survival remarkably decreases in 
low socioeconomic status (Adler and Ostrove, 1999). It is 
also shown that people with high knowledge level expose 
lower to bladder cancer risk factors, including smoking. 
As a result they less suffer from bladder cancer (Yang et 
al., 2010). Also, in those with high education and income, 
better bladder cancer survival is observed (Mackillop et 
al., 1997; Hussain et al., 2008). 
To investigate the status of countries, indicators are 
defined. One of the indicators is Human Development 
Index (HDI). The index assesses the position of a country 
in three basic aspects of development, and is a composite 
index of longevity, knowledge, and standard of living. 
Longevity is measured with life expectancy at birth, 
knowledge with potential years of education, and adequate 
standard of living with income or per GDP capita (Malik, 
2013). 
A number of studies showed the effective role of 
HDI in cancer incidence and mortality (Ghoncheh et al., 
2015). There was no a comprehensive study on bladder 
cancer incidence and mortality in Asia. It is necessary to 
know information on incidence and mortality for health 
planning and research activities. Considering the possible 
role, the aim of this study was to evaluate the incidence 
and mortality of the cancer, and their relationship with 
HDI and its components in Asia in 2012.
Materials and Methods
This study was an ecologic study in Asia for 
assessment the correlation between age-specific incidence 
and mortality rate (ASR) with Human Development Index 
(HDI) and its details that include: Life expectancy at birth, 
Mean years of schooling and Gross national income per 
capita. Data about the age-specific incidence and mortality 
rate (ASR) for every Asian counter for year 2012 get from 
global cancer project that available in (http://globocan.
iarc.fr/Default.aspx) and Human Development Index 
(HDI) from Human Development Report 2013 (Malik, 
2013) that include information about HDI and its details 
for every country in the word for year 2012. 
Method of estimate the age-specific Incidence and 
mortality rates in global cancer project by international 
agency for research on cancer 
Age-specific incidence rate estimate 
The methods of estimation are country specific and 
the quality of the estimation depends upon the quality 
and on the amount of the information available for each 
country. In theory, there are as many methods as countries, 
and because of the variety and the complexity of these 
methods, an overall quality score for the incidence and 
mortality estimates combined is almost impossible to 
establish. However an alphanumeric scoring system which 
independently describes the availability of incidence 
and mortality data has been established at the country 
level. The combined score is presented together with the 
estimates for each country with an aim of providing a 
broad indication of the robustness of the estimation.
The methods to estimate the sex- and age-specific 
incidence rates of cancer for a specific country fall into 
one of the following broad categories, in priority order:
1- Rates projected to 2012 (38 countries)-2- Most 
recent rates applied to 2012 population (20 countries)-
3-Estimated from national mortality by modelling, using 
incidence mortality ratios derived from recorded data 
in country-specific cancer registries (13 countries)-4- 
Estimated from national mortality estimates by modelling, 
using incidence mortality ratios derived from recorded 
data in local cancer registries in neighboring countries (9 
European countries)-5-Estimated from national mortality 
estimates using modelled survival (32 countries)-6- 
Estimated as the weighted average of the local rates 
(16 countries)-7- One cancer registry covering part of a 
country is used as representative of the country profile (11 
countries)-8-Age/sex specific rates for “all cancers” were 
partitioned using data on relative frequency of different 
cancers (by age and sex) (12 countries)-9- The rates are 
those of neighboring countries or registries in the same 
area (33 countries) (Ferlay et al., 2013; Lyon, 2013; Ferlay 
et al., 2015).
Age-specific mortality rate estimate 
Depending of the degree of detail and accuracy of the 
national mortality data, six methods have been utilized in 
the following order of priority:
1-Rates projected to 2012 (69 countries)-2- Most 
recent rates applied to 2012 population (26 countries)-3- 
Estimated as the weighted average of regional rates (1 
country)-4- Estimated from national incidence estimates 
by modelling, using country-specific survival (2 
countries)-5-Estimated from national incidence estimates 
using modelled survival (83 countries)-6-The rates are 
those of neighboring countries or registries in the same 
area (3 countries) (Ferlay et al., 2013; Lyon, 2013; Ferlay 
et al., 2015).
Human Development Index (HDI)
Human Development Index (HDI), a composite 
measure of indicators along three dimensions: life 
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expectancy, educational attainment and command over 
the resources needed for a decent living. All groups 
and regions have seen notable improvement in all HDI 
components, with faster progress in low and medium 
HDI countries. On this basis, the world is becoming 
less unequal. Nevertheless, national averages hide large 
variations in human experience. Wide disparities remain 
within countries of both the North and the South, and 
income inequality within and between many countries 
has been rising (Malik, 2013).
Statistical analysis
In this study, we use of correlation bivariate method for 
assessment the correlation between age-specific incidence 
and mortality rate (ASR) with Human Development Index 
(HDI) and its details that include: Life expectancy at 
birth, Mean years of schooling and Gross national income 
(Burger et al.) per capita. Statistical significance was 
assumed if P<0.05. All reported P-values are two-sided. 
Statistical analyses were performed using SPSS (Version 
15.0, SPSS Inc).
Results 
A total of 696231, bladder cancer cases were 
recorded in Asian countries in 2012. Overall, 478,069 
cases (68.66%) were males, and 218,162 cases (31.34%) 
females. Sex ratio in Asia was 2.19. The five countries with 
the highest number of new patients were china (404,996 
cases), Japan (107,898 cases), India (63,097 cases), Korea 
(31,269 cases), and Vietnam (14,203 cases), respectively. 
The countries included a total of 621,463 cases (8.26%) 
in Asia. 
Among Asian countries, five countries with the highest 
standardized incidence rates of the cancer were Korea 
with 41.8 per 100,000, Mongolia with 32.5 per 100,000, 
Japan with 29.9 per 100,000, China with 22.7 per 100,000, 
and Tajikistan with 21.7 per 100,000, respectively. Five 
countries with the lowest standardized incidence rates 
of the cancer were Timor-Leste with 2.3 per 100,000, 
Kuwait with 2.6 per 100,000, Indonesia with 2.8 per 
100,000, Pakistan with 3 per 100,000, and Thailand 
with 3.1 per 100,000, respectively. The number, crude, 
and standardized incidence rates of the cancer in Asian 
countries based on sex are presented in Table 1. Countries 
in the table are sorted from high to low based on the 
standardized incidence rate. The countries with the highest 
and lowest standardized incidence rate in both sexes are 
observable in Table 1 and Figure 1.
However, in2012, in Asia, the number of deaths due 
to bladder cancer was 524,465 cases, 351,466 cases 
(67.01%) in men and 172,999 cases (32.92%) in women. 
The sex ratio (male to female) of mortality was equal 
to2.03. The five countries with the highest number of 
deaths were china (325,166 cases), India (59,041 cases), 
Japan (52,326 cases), Vietnam (12,931 cases), and Korea 
(10,746 cases), respectively. The countries included a total 
of 460,210cases (87.74%) of the total mortality in Asia. 
In Asian countries, 5 countries with the highest 
standardized mortality rates from the cancer were 
Mongolia with 25.3 per 100,000, Tajikistan with 19.8 per 
100,000, Kyrgyzstan with 19.6 per 100,000, Kazakhstan 
with 18 per 100,000, and China with 17.9 per 100,000, 
respectively. Five countries with the lowest standardized 
mortality rates from the cancer were Kuwait with 1.6 per 
100,000, Lao PDR with 2.2 per 100,000, Timor-Leste 
with 2.3 per 100,000, Thailand with 2.5 per 100,000, and 
Indonesia with 2.5 per 100,000, respectively. The number, 
crude, and standardized mortality rates of the cancer in 
Asian countries based on sex are presented in Table 2. 
Countries in the table are sorted from high to low based 
on the standardized mortality rate. The countries with 
the highest and lowest standardized mortality rate are 
observable in both sexes in Table 2 and Figure 1.
In Table 3, amounts related to HDI and its components 
for each of the Asian countries (sorted based on HDI) 
is shown. Accordingly, Asian countries are classified 
according to HDI as follows: three countries in the very 
high category, four countries in high, thirty five countries 
Figure 2. Correlation between HDI and Standardized 
Incidence of Bladder Cancer in Asia in 2012
	  
Figure 1. Standardized and Incidence Rates of 
Mortality of Bladder Cancer in twenty Asian Countries 
with the Highest Standardized and Incidence Rates 
in 2012
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Table 1. Number, crude and standardized incidence rate of bladder cancer in Asian countries in 2012 (Sorted 
by age standardized rates from highest to lowest)
Bladder- Estimated incidence, all ages: 
both sexes
Bladder- Estimated incidence, all 
ages: male
Bladder- Estimated incidence, all ages: 
female
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Lebanon 777 18.1 16.6 Lebanon 618 29.5 29.1 Lebanon 159 7.2 6.1
Turkey 10757 14.4 15.2 Turkey 9396 25.3 28.7 Iraq 495 3.0 5.2
Israel 1414 18.4 12.6 Armenia 495 34.2 27.3 Israel 281 7.2 4.3
Armenia 554 17.8 12.3 Israel 1133 29.8 22.7 Turkey 1361 3.6 3.5
Iraq 1840 5.5 11.4 Iraq 1345 7.9 19.9 Syrian Arab Republic 248 2.4 3.5
Syrian Arab 
Republic 1300 6.2 9.6
Syrian Arab 
Republic 1052 9.8 16.1
Iran, Islamic 
Republic of 1066 2.9 3.4
Iran, Islamic 
Republic of 5343 7.1 8.3 Kazakhstan 945 12.0 14.9 Kuwait 14 1.2 2.7
State of 
Palestine 153 3.6 7.6
Iran, Islamic 
Republic of 4277 11.2 13.2 State of Palestine 27 1.3 2.5
Jordan 269 4.2 7.1 State of Palestine 126 5.8 13.1
Korea, 
Democratic 
Republic of
495 4.0 2.5
Kazakhstan 1146 7.0 6.7 Jordan 235 7.1 12.3 United Arab Emirates 13 0.5 2.4
Bahrain 41 3.0 6.3 Japan 16755 27.2 9.8 Oman 15 1.3 2.3
Japan 22042 17.4 5.6 Bahrain 35 4.1 9.6 Japan 5287 8.1 2.2
Kuwait 75 2.6 5.5 Korea, Republic of 3305 13.6 9.6 Armenia 59 3.6 2.2
Qatar 32 1.7 5.3 Georgia 279 13.8 8.4 Bahrain 6 1.2 2.1
Korea, Repub-
lic of 4097 8.4 5.2
Korea, 
Democratic 
Republic of
975 8.1 7.9 Qatar 2 0.4 1.9
Oman 73 2.5 4.8 Kuwait 61 3.5 7.1 Kazakhstan 201 2.4 1.8
Korea, 
Democratic 
Republic of
1470 6.0 4.6 Singapore 262 9.9 7.0 Jordan 34 1.1 1.8
United Arab 
Emirates 75 0.9 4.3 Qatar 30 2.0 6.7 Singapore 76 2.9 1.8
Singapore 338 6.4 4.3 Oman 58 3.4 6.7 Korea, Republic of 792 3.2 1.7
Georgia 331 7.7 4.1 Timor-Leste 16 2.6 6.6 Pakistan 947 1.1 1.6
Malaysia 890 3.0 3.7 Malaysia 718 4.8 6.1 Turkmenistan 33 1.3 1.5
Saudi Arabia 596 2.1 3.6 Turkmeni-stan 96 3.8 5.9 Afghanistan 109 0.7 1.5
Timor-Leste 18 1.5 3.5 Kyrgyzstan 97 3.6 5.8 China 2.1 1.4
Turkmenistan 129 2.5 3.5 Indonesia 5705 4.7 5.8 Cambodia 80 1.1 1.4
Pakistan 3967 2.2 3.4 Saudi Arabia 505 3.2 5.7 Malaysia 172 1.2 1.4
Afghanistan 458 1.4 3.3 United Arab Emirates 62 1.1 5.2 Tajikistan 31 0.9 1.3
Indonesia 6978 2.9 3.2 Tajikistan 92 2.6 5.1 Saudi Arabia 91 0.7 1.2
Tajikistan 123 1.7 3.0 Afghanistan 349 2.0 5.1 Myanmar 267 1.1 1.2
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Table 1. Number, crude and standardized incidence rate of bladder cancer in Asian countries in 2012 (Sorted 
by age standardized rates from highest to lowest)
Bladder- Estimated incidence, all ages: 
both sexes
Bladder- Estimated incidence, all 
ages: male
Bladder- Estimated incidence, all ages: 
female
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China 55486 4.1 3.0 Pakistan 3020 3.3 5.1 Azerbaijan 70 1.5 1.2
Kyrgyzstan 112 2.1 2.8 China 41993 5.9 4.8 Thailand 616 1.7 1.2
Azerbaijan 259 2.7 2.7 Azerbaijan 189 4.0 4.7 Indonesia 1273 1.0 1.1
Thailand 2537 3.6 2.7 Thailand 1921 5.6 4.5 Uzbekistan 108 0.8 0.9
Uzbekistan 461 1.6 2.3 Uzbekistan 353 2.5 3.8 Lao PDR 20 0.6 0.9
Cambodia 203 1.4 2.2 Maldives 5 3.1 3.8 Nepal 101 0.6 0.9
Myanmar 870 1.8 2.1 Yemen 166 1.3 3.6 Georgia 52 2.3 0.9
Lao PDR 83 1.3 2.1 Lao PDR 63 2.0 3.5 Philippines 310 0.6 0.9
Maldives 5 1.5 2.0 Nepal 295 1.9 3.3 Bhutan 2 0.6 0.9
Nepal 396 1.3 2.0 Brunei 7 3.4 3.2 Sri Lanka 105 1.0 0.7
Sri Lanka 484 2.3 1.8 Myanmar 603 2.5 3.2 Timor-Leste 2 0.3 0.7
Yemen 179 0.7 1.8 Sri Lanka 379 3.6 3.1 India 3122 0.5 0.6
India 16273 1.3 1.6 Cambodia 123 1.7 3.1 Bangladesh 319 0.4 0.6
Brunei 7 1.7 1.6 India 13151 2.0 2.7 Kyrgyzstan 15 0.5 0.6
Bangladesh 1672 1.1 1.6 Bangladesh 1353 1.8 2.5 Viet Nam 218 0.5 0.5
Philippines 989 1.0 1.5 Philippines 679 1.4 2.3 Mongolia 4 0.3 0.3
Mongolia 23 0.8 1.1 Mongolia 19 1.4 2.2 Yemen 13 0.1 0.3
Viet Nam 905 1.0 1.1 Viet Nam 687 1.5 1.8 Brunei 0 0.0 0.0
Bhutan 5 0.7 1.0 Bhutan 3 0.8 1.1 Maldives 0 0.0 0.0
in the middle category, three countries in low, and one in 
the unknown category.
Standardized incidence rate and HDI
A negative correlation was seen between the 
standardized incidence rate of bladder cancer and HDI 
about 0.241. This association was not statistically 
significant (p=0.106). There was a positive correlation 
between the standardized incidence rate and life 
expectancy at birth about 0.103 (p=0.498), positive 
correlation between the standardized incidence rate and 
mean years of schooling about 0.405 (p=0.005), and 
negative correlation between the level of income per each 
person of the population and the standardized incidence 
rate equal to -0.031 (p=0.838). (Figure 2)
In men, a positive correlation of 0.236 was observed 
between the standardized incidence rate of bladder cancer 
and HDI. It was not statistically significant (p=0.114). 
There was a positive correlation between the standardized 
incidence rate and life expectancy at birth about 0.102 
(p=0.502), a positive correlation between mean years 
of schooling and the standardized incidence rate about 
0.410 (p=0.005), and negative correlation between the 
level of income per each person of the population and 
the standardized incidence rate equal to -0.044 (p=0.774). 
In women, a negative correlation of -0.250 was 
observed between the standardized incidence rate of 
bladder cancer and HDI. It was not statistically significant 
(p=0.094). There was a positive correlation between the 
standardized incidence rate and life expectancy at birth 
about 0.092 (p=0.545), positive correlation between mean 
years of schooling and the standardized incidence rate 
about 0.419 (p=0.04), and negative correlation between 
the level of income per each person of the population and 
the standardized incidence rate equal to -0.015 (p=0.923). 
The standardized mortality rate and HDI
There was between the standardized mortality rate for 
bladder cancer and HDI a negative correlation of 0.025 
(p=0.871), expectancy at birth a negative correlation of 
-0.173 (p=0.252), mean years of schooling a negative 
correlation equal to -0.233 (p=0119), and the level 
of income per each person of population a negative 
correlation of -0.213(p=0.155). (Figure 3)
In men, there was between the standardized mortality 
rate for bladder cancer and HDI a negative correlation 
of 0.118 (p=0.903), expectancy at birth a negative 
correlation of 0.165 (p=0.274), mean years of schooling 
a positive correlation equal to 0.253 (p=0.090), and the 
level of income per each person of population a negative 
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Table 2. Number, Crude and Standardized Mortality Rates for Bladder Cancer in Asian Countries in 2012 
(Sorted by age standardized rates from highest to lowest)
Bladder- Estimated mortality, all 
ages: both sexes
Bladder- Estimated mortality, all ages: 
male
Bladder- Estimated mortality, all ages: 
female
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Turkey 4690 6.3 6.6 Turkey 4099 11.0 12.8 Iraq 275 1.6 2.9
Iraq 1016 3.0 6.3 Iraq 741 4.4 11.4 Lebanon 64 2.9 2.4
Lebanon 307 7.2 6.3 Armenia 221 15.3 11.3 Syrian Arab Republic 125 1.2 1.8
Armenia 248 8.0 5.0 Lebanon 243 11.6 11.0 Kuwait 7 0.6 1.6
Syrian Arab 
Republic 653 3.1 4.9
Syrian Arab Re-
public 528 4.9 8.3 Turkey 591 1.6 1.5
State of Palestine 74 1.7 3.9 State of Palestine 61 2.8 7.0 Iran, Islamic Republic of 453 1.2 1.4
Iran, Islamic 
Republic of 2280 3.0 3.5 Kazakhstan 366 4.7 6.1 State of Palestine 13 0.6 1.2
Jordan 121 1.9 3.2 Iran, Islamic Re-public of 1827 4.8 5.5 Oman 7 0.6 1.2
Kazakhstan 447 2.7 2.6 Jordan 105 3.2 5.5 Afghanistan 73 0.5 1.1
Afghanistan 307 0.9 2.5 Timor-Leste 10 1.7 4.3 Korea, Democratic Republic of 256 2.0 1.1
Oman 34 1.2 2.5 Israel 227 6.0 3.9 Pakistan 571 0.6 1.0
Bahrain 11 0.8 2.4 Bahrain 9 1.1 3.9 Israel 77 2.0 0.9
Israel 304 4.0 2.2 Afghanistan 234 1.4 3.8 Armenia 27 1.6 0.9
Timor-Leste 11 0.9 2.2 Korea, Democratic Republic of 430 3.6 3.8 Jordan 16 0.5 0.9
Kuwait 26 0.9 2.1 Oman 27 1.6 3.4 Bhutan 2 0.6 0.9
Pakistan 2396 1.3 2.1 Georgia 112 5.5 3.1 Cambodia 47 0.6 0.9
Korea, 
Democratic 
Republic of
686 2.8 2.1 Kyrgyzstan 50 1.9 3.1 Bahrain 2 0.4 0.8
Indonesia 3599 1.5 1.7 Pakistan 1825 2.0 3.1 Myanmar 166 0.7 0.8
Qatar 7 0.4 1.6 Indonesia 2940 2.4 3.1 Turkmenistan 15 0.6 0.7
Turkmenistan 58 1.1 1.6 Turkmenistan 43 1.7 2.9 Tajikistan 16 0.4 0.7
Tajikistan 64 0.9 1.6 Tajikistan 48 1.4 2.8 Japan 2462 3.8 0.7
United Arab 
Emirates 18 0.2 1.5 Korea, Republic of 955 3.9 2.6 United Arab Emirates 3 0.1 0.7
Georgia 133 3.1 1.5 Kuwait 19 1.1 2.5 Kazakhstan 81 1.0 0.7
Kyrgyzstan 58 1.1 1.5 Japan 5168 8.4 2.4 China 6762 1.0 0.6
Japan 7630 6.0 1.4 Qatar 7 0.5 2.4 Korea, Republic of 375 1.5 0.6
Korea, Republic 
of 1330 2.7 1.4 Yemen 105 0.8 2.4 Nepal 64 0.4 0.6
Saudi Arabia 211 0.7 1.4 Saudi Arabia 178 1.1 2.3 Indonesia 659 0.5 0.6
China 2.0 1.4 China 20058 2.8 2.2 Thailand 312 0.9 0.6
Cambodia 121 0.8 1.4 Lao PDR 39 1.2 2.2 Lao PDR 12 0.4 0.5
Myanmar 542 1.1 1.3 Thailand 976 2.8 2.2 Uzbekistan 56 0.4 0.5
Lao PDR 51 0.8 1.3 Nepal 189 1.2 2.2 Azerbaijan 31 0.7 0.5
Thailand 1288 1.8 1.3 Azerbaijan 83 1.8 2.1 Saudi Arabia 33 0.3 0.5
Nepal 253 0.8 1.3 Cambodia 74 1.0 2.1 Singapore 20 0.8 0.4
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Table 2. Number, , Crude and Standardized Mortality Rates for Bladder Cancer in Asian Countries in 2012 
(Sorted by age standardized rates from highest to lowest)
Bladder- Estimated mortality, all ages: 
male
Bladder- Estimated mortality, all ages: 
female
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Azerbaijan 114 1.2 1.2 Myanmar 376 1.6 2.1 Philippines 138 0.3 0.4
Uzbekistan 231 0.8 1.2 Uzbekistan 175 1.3 2.0 Bangladesh 196 0.3 0.4
Yemen 113 0.4 1.2 United Arab Emirates 15 0.3 1.9 India 1859 0.3 0.4
Malaysia 264 0.9 1.1 Malaysia 221 1.5 1.9 Timor-Leste 1 0.2 0.4
Bangladesh 1016 0.7 0.9 India 7664 1.2 1.6 Malaysia 43 0.3 0.4
Singapore 75 1.4 0.9 Bangladesh 820 1.1 1.5 Georgia 21 0.9 0.3
India 9523 0.8 0.9 Singapore 55 2.1 1.5 Sri Lanka 47 0.4 0.3
Sri Lanka 216 1.0 0.8 Sri Lanka 169 1.6 1.4 Mongolia 4 0.3 0.3
Bhutan 4 0.5 0.7 Philippines 292 0.6 1.1 Kyrgyzstan 8 0.3 0.3
Philippines 430 0.4 0.7 Viet Nam 367 0.8 1.0 Viet Nam 119 0.3 0.3
Viet Nam 486 0.5 0.6 Brunei 2 1.0 0.9 Yemen 8 0.1 0.2
Mongolia 12 0.4 0.5 Mongolia 8 0.6 0.8 Brunei 0 0.0 0.0
Brunei 2 0.5 0.5 Bhutan 2 0.5 0.7 Maldives 0 0.0 0.0
Maldives 1 0.3 0.3 Maldives 1 0.6 0.6 Qatar 0 0.0 0.0
Table 3. Human Development Index and its Components in Asian Countries in 2012
POPULATION
Human 
Development 
Index(HDI)
Life expectancy 
at birth
Mean Year of 
schooling
Gross national 
income (Burger 
et al.) per capita
Very high human 
development
Japan 0.912 83.6 11.6 32545
Korea, Republic of 0.909 80.7 11.6 28231
Israel 0.9 81.9 11.9 26224
Singapore 0.895 81.2 10.1 52613
Brunei 0.855 78.1 8.6 45690
Qatar 0.834 78.5 7.3 87478
United Arab Emirates 0.818 76.7 8.9 42716
High human 
development
Bahrain 0.796 75.2 9.4 19154
Kuwait 0.79 74.7 6.1 52793
Saudi Arabia 0.782 74.1 7.8 22616
Malaysia 0.769 74.5 9.5 13676
Kazakhstan 0.754 67.4 10.4 10451
Georgia 0.745 73.9 12.1 5005
Lebanon 0.745 72.8 7.9 12364
Iran, Islamic Republic of 0.742 73.2 7.8 10695
Azerbaijan 0.734 70.9 11.2 8153
Oman 0.731 73.2 5.5 24092
Armenia 0.729 74.4 10.8 5540
Turkey 0.722 74.2 6.5 13710
Sri Lanka 0.715 75.1 9.3 5170
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correlation of 0.223 (p=0.136).
In women, there was between the standardized 
mortality rate for bladder cancer and HDI a negative 
correlation of 0.014 (p=0.927), expectancy at birth a 
negative correlation of 0.178 (p=0.237), mean years of 
schooling a positive correlation equal to 0.241(p=0.106), 
and the level of income per each person of population a 
negative correlation of 0.190 (p=0.207). 
Discussion
Less than 35% of bladder cancer cases occur in Asia. 
Given that more than 60 percent of people in the world are 
in Asia, and most countries in the region are developing, 
it is expected that bladder cancer is associated with a 
significant increase in the continent. Therefore, health 
macro policies to deal with this cancer in the future 
are an important need (Ferlay et al., 2013; Lyon, 2013; 
Keyghobadi et al., 2014).
Our results showed that most standardized incidence 
rate of bladder cancer was related to the countries such as 
Republic of Korea, Mongolia, Japan, China, and Tajikistan. 
The countries had middle and high HDI. However, in our 
study, no strong correlation was found between HDI and 
incidence of bladder cancer. Other studies have shown that 
Table 3. Human Development Index and its Components in Asian Countries in 2012
POPULATION
Human 
Development 
Index(HDI)
Life expectancy 
at birth
Mean Year of 
schooling
Gross national 
income (Burger 
et al.) per capita
Medium human 
development
Jordan 0.7 73.5 8.6 5272
China 0.699 73.7 7.5 7945
Turkmenistan 0.698 65.2 9.9 7782
Thailand 0.69 74.3 6.6 7722
Maldives 0.688 77.1 5.8 7478
Mongolia 0.675 68.8 8.3 4245
State of Palestine 0.67 73 8 3359
Philippines 0.654 69 8.9 3752
Uzbekistan 0.654 68.6 10 3201
Syrian Arab Republic 0.648 76 5.7 4674
Indonesia 0.629 69.8 5.8 4154
Kyrgyzstan 0.622 68 9.3 2009
Tajikistan 0.622 67.8 9.8 2119
Viet Nam 0.617 75.4 5.5 2970
Iraq 0.59 69.6 5.6 3557
Timor-Leste 0.576 62.9 4.4 5446
India 0.554 65.8 4.4 3285
Cambodia 0.543 63.6 5.8 2095
Lao PDR 0.543 67.8 4.6 2435
Bhutan 0.538 67.6 2.3 5246
Low human 
development
Bangladesh 0.515 69.2 4.8 1785
Pakistan 0.515 65.7 4.9 2566
Myanmar 0.498 65.7 3.9 1 817
Nepal 0.463 69.1 3.2 1137
Yemen 0.458 65.9 5.3 928
Afghanistan 0.374 49.1 3.1 1000
Other countries or 
territories
Korea, Democratic People’s 
Rep. of - - - -
Figure 3. Correlation between HDI and Standardized 
Mortality Rates for bladder Cancer in Asia in 2012
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there was a significant difference the incidence of bladder 
cancer in higher HDI countries than low HDI countries, 
but a little difference was observed in the mortality rate 
between the two groups of countries (Bray et al., 2012). 
The incidence of bladder cancer rises due to higher 
exposure to causal factors such as tobacco and chemicals 
industries, along with development (Burger et al., 2013).
The incidence of bladder cancer in the whole of Asia 
is three to four times less than European and American 
countries (Ferlay et al., 2013; Lyon, 2013). It is shown that 
the incidence and deaths from bladder cancer is declining 
in Europe and North America, while its incidence is 
increasing in Asian countries (Ploeg et al., 2009). This is 
due to shifting in smoking consumption from developed 
countries to developing countries and less developed, so 
that in North America and European countries in the early 
and mid-twentieth century, smoking has declined in both 
men and women. In the late twentieth century, smoking 
in less developed countries had significantly increased in 
men and women (Lopez et al., 1994; Mackay and Eriksen, 
2002; Consortium, 2004; Delclos and Lerner, 2008; Razi 
et al., 2014). The justification for this is that in the last half 
century, consumption of hazardous industrial chemicals 
has been decreased in less developed countries, while it 
has been increased in developing countries in the same 
period (Delclos and Lerner, 2008; Ploeg et al., 2009). 
In our study, no relationship was found between life 
expectancy as one of the dimensions of the HDI, and the 
standardized incidence and mortality rates. However, with 
increasing age, the incidence of bladder cancer increases. 
The peak of bladder cancer incidence occurs in 65 years, 
but in many developed countries life expectancy is less 
than from the peak. As a result, the risk of cancer is lower 
in them (Malats and Real, 2015). It is also necessary to 
note that the relationship between age and cancer could 
be due to previous exposure to risk factors for bladder 
cancer and their cumulative effect. Therefore, cancer 
usually occurs in old age.
One of the dimensions of HDI is the level of income, 
characterized by gross domestic product. In our study, 
there was no relationship between the income level, 
and standardized incidence and mortality rates. Studies 
have shown that cancer mortality is higher in low-
income countries (Soerjomataram et al., 2012). A direct 
relationship was also observed between income level 
and bladder cancer survival rate. In other words, the 
survival rate increases with raising the income level 
(Mackillop et al., 1997). This may be due to better access 
to high quality health care. Ezzati revealed that smoking 
consumption is changing from countries with high income 
to low-middle income countries. Many lower and middle-
income countries still are experiencing the first stage of 
the epidemiological transition of smoking (Ezzati and 
Lopez, 2003a; 2003b). Ward showed that even without 
regard to sex, in low-income countries smoking is twice 
than high income countries (Ward et al., 2004). Ploeg 
also indicated that in low-income countries, chemical 
consumption associated with bladder cancer has been 
increased, while in the same period, industrial use of 
such hazardous substances is declining in high-income 
countries. It is expected in the near future, the incidence 
of bladder cancer will significantly increase in developing 
countries (Ploeg et al., 2009). 
Another dimension of HDI was the level of education 
or awareness, characterized by mean years of schooling. 
In our study, there was no relationship between the 
education level and standardized death rate. However, a 
significant relationship was found between standardized 
incidence rate and the education level. Hussain has shown 
that the survival rate of bladder cancer is more in people 
with higher education (Hussain et al., 2008). It seems 
that in developed countries, better treatment, appropriate 
lifestyle, reducing smoking, the mechanization of industry 
and less use of hazardous chemicals, including aromatic 
amines, better access to health services, and reducing 
infectious diseases lead to decrease bladder cancer 
incidence and mortality. In developing and less developed 
countries, poor lifestyle, smoking, the use of traditional 
methods in the industry, excessive exposure to dangerous 
chemicals, and the lack of adequate infrastructure for 
the implementation of comprehensive cancer control 
programs lead to more likely bladder cancer incidence 
and die from it (Messing et al., 1995; Ploeg et al., 2009).
Bladder cancer incidence is higher in developed 
countries, but the rate is declining, and in less developed 
and developing countries it is growing. In contrast, bladder 
cancer mortality in developed countries is less and the 
survival of bladder cancer is more, while in developing 
and the less developed countries bladder cancer mortality 
is higher and survival is lower. There was no statistically 
significant correlation between the standardized incidence 
rate of bladder cancer, and the HDI and its dimensions, 
except for the level of education. No relationship was 
found between standardized mortality rate, and the HDI 
and its dimensions.
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